8-K: Chimerix Announces Second Quarter 2024 Financial Results and Provides Clinical Pipeline Update

Chimerix reported its second quarter 2024 financial results, highlighted progress in its Phase 3 ACTION study for dordaviprone, and provided updates on its ONC206 program.

Summary

• Chimerix announced its financial results for the second quarter of 2024, reporting a net loss of $20.7 million, or $0.23 per share.
• Research and development expenses increased to $18.4 million, while general and administrative expenses rose to $4.5 million for the quarter.
• The company has $171.5 million in capital available to fund operations as of June 30, 2024, with no outstanding debt.
• The Phase 3 ACTION study for dordaviprone is on track, with the first interim overall survival data expected in the third quarter of 2025.
• ONC206 Phase 1 trials have reached dose level 10, demonstrating dose-proportional exposure with no dose-limiting toxicities observed to date.
• Enrollment in the ONC206 dose escalation trials is expected to be completed by the end of 2024.
• A Provisional Determination application for dordaviprone has been filed in Australia, marking the second step towards potential Provisional Approval.
• Chimerix estimates that approximately 2,000 patients in the U.S. and 5,000 globally have H3 K27M-mutant diffuse glioma, the target of dordaviprone.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and a strong cash position, the increased net loss and R&D expenses temper the overall sentiment. The company is making progress but is not yet profitable.

Positives

• The Phase 3 ACTION study for dordaviprone is on track, with a clear timeline for interim data.
• ONC206 is progressing well in Phase 1 trials, showing promising pharmacokinetic data and a good safety profile.
• The filing for Provisional Determination in Australia expands the potential market for dordaviprone.
• The company has a strong cash position with no debt, providing financial stability.
• ONC206 has shown monotherapy activity in preclinical models, suggesting potential for broader applications.
• The company has a robust business development search and evaluation process.

Negatives

• Chimerix reported a net loss of $20.7 million for the second quarter of 2024, an increase from the $18.6 million loss in the same period of 2023.
• Research and development expenses increased to $18.4 million for the second quarter of 2024, compared to $16.9 million for the same period in 2023.
• General and administrative expenses increased to $4.5 million for the second quarter of 2024, compared to $4.4 million for the same period in 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• There are risks related to obtaining and maintaining accelerated approval for their products.
• The timing, completion, and outcome of the Phase 3 ACTION study are subject to risks.
• There are risks associated with repeating positive results from prior studies in future studies.
• The clinical development of ONC206 is subject to risks.
• The company's ability to successfully commercialize its products is not guaranteed.

Future Outlook

The company anticipates interim overall survival data from the ACTION study in the third quarter of 2025, expects to complete enrollment in ONC206 dose escalation trials by the end of 2024, and is pursuing Provisional Registration for dordaviprone in Australia with potential commercial availability in 2026.

Management Comments

• Mike Andriole, Chief Executive Officer of Chimerix, stated that they continued their strong execution of the Phase 3 ACTION study and expect the first interim overall survival data in the third quarter of 2025.
• Mr. Andriole also mentioned that they are making great strides advancing ONC206 through the remaining dose cohorts in two Phase 1 trials.
• Mr. Andriole added that their team continues to be driven by the urgent need of patients focusing on indications where the unmet medical need remains frustratingly high.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for rare and aggressive cancers. The progress of dordaviprone and ONC206 is of interest to the neuro-oncology community, as they target unmet needs in H3 K27M-mutant glioma and other CNS tumors. The company's focus on orphan drug designations and accelerated approval pathways is also a common strategy in this sector.

Comparison to Industry Standards

• Chimerix's dordaviprone targets H3 K27M-mutant diffuse glioma, a rare and aggressive cancer with no approved therapies, setting it apart from many other oncology drug developers.
• The company's Phase 2 data for dordaviprone showed a median overall survival of 13.7 months, compared to a historical median of 5.1 months, indicating a significant improvement over standard care.
• The Phase 3 ACTION trial is designed with multiple interim analysis points, which is a common practice in oncology trials to allow for early assessment of efficacy.
• ONC206's dual mechanism of action as a ClpP agonist and DRD2 antagonist is a novel approach, differentiating it from other CNS tumor treatments.
• The company's focus on both CNS and non-CNS tumors with ONC206 expands its potential market reach compared to companies focused on a single tumor type.
• Chimerix's financial position with $171.5 million in capital and no debt is relatively strong compared to many other small-cap biotech companies, providing a buffer for ongoing clinical development.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the clinical progress.
• Employees are likely to be motivated by the advancements in the pipeline.
• Patients with H3 K27M-mutant glioma and other CNS tumors may have increased hope for new treatment options.
• Analysts and investors will be closely monitoring the upcoming data readouts and regulatory milestones.

Next Steps

• Chimerix will continue enrolling patients in the Phase 3 ACTION study.
• The company will complete enrollment in the ONC206 dose escalation trials by the end of 2024.
• Chimerix will assess objective responses in ONC206 dose cohorts in the first half of 2025.
• The company will continue to advance the Provisional Registration process for dordaviprone in Australia.
• Chimerix will participate in upcoming healthcare conferences.

Key Dates

Keywords

dordaviprone, ONC206, H3 K27M-mutant glioma, Phase 3 ACTION study, clinical trials, biopharmaceutical, CNS tumors, imipridone, ClpP agonist, DRD2 antagonist